Webinars & Videos

In the highly competitive peptide market, speed is critical for the success of novel peptide therapeutic development. This case study shows how WuXi TIDES scientists accelerate the development of a complex peptide conjugate in terms of both speed and quality. In just 10 months, we were able to optimize the process of an 87-step synthesis and provide GLP and GMP API supplies.

Radionuclide Drug Conjugates (RDCs) have shown great potential in early-stage tumor imaging and radioactive nuclide therapy. Read this WuXi TIDES case study to learn how the seamless transition from discovery to process development and manufacturing, across both small molecules and peptides, accelerated development of a challenging RDC candidate and IND submission. Milligram-scale discovery synthesis was completed in 1 month, and kilogram-scale manufacturing in just 3 months!

Peptide-oligonucleotide conjugates are made up of peptide and oligonucleotide components. These cutting-edge molecules have many applications in biomedicine. Dive into the video to learn more.

In this article, we will look specifically at the development challenge faced when moving a peptide-drug conjugate (PDC) from pre-clinical (gram-scale) to phase I (kg-scale). New modality conjugations with HPAPIs and peptides – particularly for oncology targets – are now an increasingly large part of the discovery pipeline.

This video demonstrate WuXi TIDES unique peptide CRDMO platform, state-of-the-art facility R&D labs, API & drug product manufacturing plants.

WuXi TIDES Oligonucleotide, Peptide & Complex Conjugates Business Introduction